Novel anti-systematic erythema lupus medicine

A systemic technology for lupus erythematosus, applied in the field of medicine, can solve the problems of large side effects and impossibility of long-term use, and achieve the effect of small side effects, low cost and significant curative effect

Inactive Publication Date: 2011-03-23
SUZHOU MAIDIXIAN PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs have a certain effect on the treatment of systemic lupus erythematosus, but the side effects are very large and cannot be used for a long time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel anti-systematic erythema lupus medicine
  • Novel anti-systematic erythema lupus medicine
  • Novel anti-systematic erythema lupus medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Accurately weigh 1 mg of triptolide, 2200 mg of brazilianin, 799 mg of borneol and 7000 mg of polyethylene glycol 4000, place them in a heating container and heat while stirring, and heat to a temperature of 125°C to obtain the drug containing Melt or emulsion or suspension of dry powder and matrix.

[0036] Prepare dripping pills: adopt advanced dropping pill machine (TZDW-1 type dropping pill machine produced by Beijing Changzheng Tianmin High-tech Co., Ltd.), and adjust the temperature control system of the dropping pill machine, so that the dripper temperature of the dropping pill machine is heated and maintained At (50°C to 90°C), the temperature of the condensing agent is cooled and maintained at (4°C to -5°C). When the temperature of the condensing agent in the dripper of the dripping machine and the coagulation column is stable at the above required temperature state, the melt or emulsion or suspension containing the above-mentioned dry powder of the drug and th...

Embodiment 2

[0040] Accurately weigh 1 mg of triptolide, 340 mg of brazilianin, 100 mg of borneol and 2000 mg of polyethylene glycol 2000, place them in a heating container and heat while stirring, and heat to a temperature of 125°C to obtain the drug containing Melt or emulsion or suspension of dry powder and matrix.

[0041] Prepare dripping pills: adopt advanced dropping pill machine (TZDW-1 type dropping pill machine produced by Beijing Changzheng Tianmin High-tech Co., Ltd.), and adjust the temperature control system of the dropping pill machine, so that the dripper temperature of the dropping pill machine is heated and maintained At (50°C to 90°C), the temperature of the condensing agent is cooled and maintained at (4°C to -5°C). When the temperature of the condensing agent in the dripper of the dripping machine and the coagulation column is stable at the above required temperature state, the melt or emulsion or suspension containing the above-mentioned dry powder of the drug and the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention pertains to the pharmaceutical technical field and in particular relates to a new systemic lupus erythematosus resistant drug. The invention comprises drop pill and oral liquid and is prepared by 0.01-0.1percent of triptolide, 3-25percent of brazilin and 1-10percent of borneol which are mixed with 65-90percent of preparation accessories by a simple technique. The novel drug of the invention has powerful treatment effect of systemic lupus erythematosus resistance on the mouse systemic lupus erythematosus disease model and also has curative effect and depression effect on the clinical treatment of human; the interaction between the three drugs of triptolide, brazilin and borneol generates remarkable coordination action and can reduce the side effect from triptolide, which leads the invention to be the most prospective nontoxic drug to resist the systemic lupus erythematosus. The invention has remarkable treatment effect, insignificant side effect, simple preparation technique and low cost and is the first choice for treating the systemic lupus erythematosus.

Description

Technical field: [0001] The invention belongs to the technical field of medicines, in particular to a new drug against systemic lupus erythematosus. Background technique: [0002] Lupus erythematosus is a disease of collagen tissue, that is, the human body's own immune system. "Lupus erythematosus" is divided into two types of lesions, systemic lupus erythematosus and discoid lupus erythematosus, which mostly occur in adolescent and childbearing women, especially young women. The peak incidence is between 15 and 40 years old, and the ratio of male to female is 1:5~9. In addition to heredity, infection, drugs, and environmental factors, the cause of the disease is also related to the endocrine system of the human body, especially female hormones, so it is more common in women. Discoid lupus erythematosus mainly manifests on the surface of the skin, while systemic lupus erythematosus manifests as persistent high fever and joint pain. When chamaea venom invades the internal o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/045A61K31/365A61K31/352A61P37/02A61P19/04
Inventor 张南
Owner SUZHOU MAIDIXIAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap